Search

Your search keyword '"Feigh, Michael"' showing total 219 results
Start Over Author "Feigh, Michael"
219 results on '"Feigh, Michael"'

1. An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD)

Author

Vacca, Michele, Kamzolas, Ioannis, Harder, Lea Mørch, Oakley, Fiona, Trautwein, Christian, Hatting, Maximilian, Ross, Trenton, Bernardo, Barbara, Oldenburger, Anouk, Hjuler, Sara Toftegaard, Ksiazek, Iwona, Lindén, Daniel, Schuppan, Detlef, Rodriguez-Cuenca, Sergio, Tonini, Maria Manuela, Castañeda, Tamara R., Kannt, Aimo, Rodrigues, Cecília M. P., Cockell, Simon, Govaere, Olivier, Daly, Ann K., Allison, Michael, Honnens de Lichtenberg, Kristian, Kim, Yong Ook, Lindblom, Anna, Oldham, Stephanie, Andréasson, Anne-Christine, Schlerman, Franklin, Marioneaux, Jonathon, Sanyal, Arun, Afonso, Marta B., Younes, Ramy, Amano, Yuichiro, Friedman, Scott L., Wang, Shuang, Bhattacharya, Dipankar, Simon, Eric, Paradis, Valérie, Burt, Alastair, Grypari, Ioanna Maria, Davies, Susan, Driessen, Ann, Yashiro, Hiroaki, Pors, Susanne, Worm Andersen, Maja, Feigh, Michael, Yunis, Carla, Bedossa, Pierre, Stewart, Michelle, Cater, Heather L., Wells, Sara, Schattenberg, Jörn M., Anstee, Quentin M., Tiniakos, Dina, Perfield, James W., Petsalaki, Evangelia, Davidsen, Peter, and Vidal-Puig, Antonio

Published
2024
Full Text
View/download PDF

6. Paraoxonase‐2 agonist vutiglabridin promotes autophagy activation and mitochondrial function to alleviate non‐alcoholic steatohepatitis

Author

Shin, Gu‐Choul, primary, Lee, Hyeong Min, additional, Kim, Nayeon, additional, Hur, Jihyeon, additional, Yoo, Sang‐Ku, additional, Park, Yun Sun, additional, Park, Hyung Soon, additional, Ryu, Dongryeol, additional, Park, Min‐Ho, additional, Park, Jung Hee, additional, Seo, Sang‐Uk, additional, Choi, Leo Sungwong, additional, Madsen, Martin Rønn, additional, Feigh, Michael, additional, Kim, Kwang Pyo, additional, and Kim, Kyun‐Hwan, additional

Published
2024
Full Text
View/download PDF

16. Evaluation of long acting GLP1R/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1/glucagon agonism in NASH patients.

Author

Monfeuga, Thomas, primary, Norlin, Jenny, additional, Bugge, Anne, additional, Gaalsgaard, Elisabeth D., additional, Prada-Medina, Cesar A., additional, Latta, Markus, additional, Veidal, Sanne S., additional, Petersen, Pia S., additional, Feigh, Michael, additional, and Holst, Dorte, additional

Published
2023
Full Text
View/download PDF

17. Resolution of NASH and hepatic fibrosis by the GLP-1R and GCGR dual-agonist cotadutide via modulating mitochondrial function and lipogenesis

Author

Boland, Michelle L., Laker, Rhianna C., Mather, Karly, Nawrocki, Arkadiusz, Oldham, Stephanie, Boland, Brandon B., Lewis, Hilary, Conway, James, Naylor, Jacqueline, Guionaud, Silvia, Feigh, Michael, Veidal, Sanne S., Lantier, Louise, McGuinness, Owen P., Grimsby, Joseph, Rondinone, Cristina M., Jermutus, Lutz, Larsen, Martin R., Trevaskis, James L., and Rhodes, Christopher J.

Published
2020
Full Text
View/download PDF

18. Increased hepatoprotective effects of the novel farnesoid X receptor agonist INT-787 versus obeticholic acid in a mouse model of nonalcoholic steatohepatitis.

Author

Adorini, Luciano, Rigbolt, Kristoffer, Feigh, Michael, Roth, Jonathan, and Erickson, Mary

Subjects
FARNESOID X receptor, NON-alcoholic fatty liver disease, LABORATORY mice, ANIMAL disease models, ALANINE aminotransferase, ASPARTATE aminotransferase
Abstract

The nuclear farnesoid X receptor (FXR), a master regulator of bile acid and metabolic homeostasis, is a key target for treatment of nonalcoholic steatohepatitis (NASH). This study compared efficacy of FXR agonists obeticholic acid (OCA) and INT-787 by liver histopathology, plasma biomarkers of liver damage, and hepatic gene expression profiles in the Amylin liver NASH (AMLN) diet–induced and biopsy-confirmed Lepob/ob mouse model of NASH. Lepob/ob mice were fed the AMLN diet for 12 weeks before liver biopsy and subsequent treatment with vehicle, OCA, or INT-787 for 8 weeks. Hepatic steatosis, inflammation, and fibrosis (liver lipids, galectin-3, and collagen 1a1 [Col1a1], respectively), as well as plasma alanine transaminase (ALT) and aspartate transaminase (AST) levels, were assessed. Hepatic gene expression was assessed in Lepob/ob mice that were fed the AMLN diet for 14 weeks then treated with vehicle, OCA, or INT-787 for 2 weeks. INT-787, which is equipotent to OCA but more hydrophilic, significantly reduced liver lipids, galectin-3, and Col1a1 compared with vehicle, and to a greater extent than OCA. INT-787 significantly reduced plasma ALT and AST levels, whereas OCA did not. INT-787 modulated a substantially greater number of genes associated with FXR signaling, lipid metabolism, and stellate cell activation relative to OCA in hepatic tissue. These findings demonstrate greater efficacy of INT-787 treatment compared with OCA in improving liver histopathology, decreasing liver enzyme levels, and enhancing gene regulation, suggesting superior clinical potential of INT-787 for the treatment of NASH and other chronic liver diseases. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

19. Therapeutic effects of ALK5i on pulmonary function and fibrosis in a high-fat diet + bleomycin-induced and spirometry-confirmed mouse model of IPF

Author

Graver Petersen, Asbjørn, primary, Bousamaki, Jamal, additional, Jul Andreasen, Laura, additional, Oró, Denise, additional, Damgård Schmidt, Jonas, additional, Nie, Yaohui, additional, Butts, Jordan, additional, Roqueta-Rivera, Manuel, additional, Björk Hansen, Henrik, additional, and Feigh, Michael, additional

Published
2023
Full Text
View/download PDF

26. Combination therapy of TERN-501, a selective agonist of thyroid hormone receptor (THR) beta with TERN-101, a farnesoid X receptor (FXR) agonist improves non-alcoholic steatohepatitis (NASH) in a GAN diet-induced and biopsy-confirmed mouse model

Author

Jones, Christopher, primary, Nielsen, Malte H., additional, Oró, Denise, additional, Feigh, Michael, additional, Teng, Xiao, additional, Lie, Anthony, additional, Ho, Gideon, additional, and Jasper, Jeffrey, additional

Published
2023
Full Text
View/download PDF

27. Differential hepatoprotective effects of semaglutide and lanifibranor in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH with advanced fibrosis and HCC

Author

Nielsen, Malte H., primary, Pors, Susanne, additional, Nøhr-Meldgaard, Jacob, additional, Madsen, Andreas Nygaard, additional, Møllerhøj, Mathias Bonde, additional, Oró, Denise, additional, Vyberg, Mogens, additional, Hansen, Henrik B., additional, and Feigh, Michael, additional

Published
2023
Full Text
View/download PDF

32. Hepatoprotective effects of the long-acting fibroblast growth factor 21 analog PF-05231023 in the GAN diet-induced obese and biopsy-confirmed mouse model of nonalcoholic steatohepatitis

Author

Nielsen, Malte Hasle, Gillum, Matthew P, Vrang, Niels, Jelsing, Jacob, Hansen, Henrik H., Feigh, Michael, Oró, Denise, Nielsen, Malte Hasle, Gillum, Matthew P, Vrang, Niels, Jelsing, Jacob, Hansen, Henrik H., Feigh, Michael, and Oró, Denise

Abstract

Fibroblast growth factor 21 (FGF21) plays a key role in hepatic lipid metabolism and long-acting FGF21 analogs have emerged as promising drug candidates for the treatment of nonalcoholic steatohepatitis (NASH). It remains to characterize this drug class in translational animal models that recapitulate the etiology and hallmarks of human disease. To this end, we evaluated the longacting FGF21 analog PF-05231023 in the GAN (Gubra Amylin NASH) diet-induced obese (DIO) and biopsy-confirmed mouse model of NASH. Male C57BL/6J mice were fed the GAN diet high in fat, fructose, and cholesterol for 34 wk before the start of the study. GAN DIO-NASH mice with biopsy-confirmed NAFLD Activity Score (NAS 5) and fibrosis (stage F1) were biweekly administered with PF-05231023 (10 mg/kg sc) or vehicle (sc) for 12 wk. Vehicle-dosed chow-fed C57BL/6J mice served as healthy controls. Pre-to-post liver biopsy histopathological scoring was performed for within-subject evaluation of NAFLD Activity Score (NAS) and fibrosis stage. Terminal endpoints included quantitative liver histology and transcriptome signatures as well as blood and liver biochemistry. PF-05231023 significantly reduced body weight, hepatomegaly, plasma transaminases, and plasma/liver lipids in GAN DIO-NASH mice. Notably, PF-05231023 reduced both NAS (2-point improvement) and fibrosis stage (1-point improvement). Improvements in NASH and fibrosis severity were supported by reduced quantitative histological markers of steatosis, inflammation, and fibrogenesis as well as improvements in disease-associated liver transcriptome signatures. In conclusion, PF-05231023 reduces NASH and fibrosis severity in a translational biopsy-confirmed mouse model of NASH, supporting development of FGF21 analogs for the treatment of NASH. NEW & NOTEWORTHY It is unclear if long-acting FGF21 analogs have antifibrotic efficacy in NASH. We therefore profiled the clinically relevant, Fibroblast growth factor 21 (FGF21) plays a key role in hepatic lipid metabolism and long-acting FGF21 analogs have emerged as promising drug candidates for the treatment of nonalcoholic steatohepatitis (NASH). It remains to characterize this drug class in translational animal models that recapitulate the etiology and hallmarks of human disease. To this end, we evaluated the long-acting FGF21 analog PF-05231023 in the GAN (Gubra Amylin NASH) diet-induced obese (DIO) and biopsy-confirmed mouse model of NASH. Male C57BL/6J mice were fed the GAN diet high in fat, fructose, and cholesterol for 34 wk before the start of the study. GAN DIO-NASH mice with biopsy-confirmed NAFLD Activity Score (NAS ≥5) and fibrosis (stage ≥F1) were biweekly administered with PF-05231023 (10 mg/kg sc) or vehicle (sc) for 12 wk. Vehicle-dosed chow-fed C57BL/6J mice served as healthy controls. Pre-to-post liver biopsy histopathological scoring was performed for within-subject evaluation of NAFLD Activity Score (NAS) and fibrosis stage. Terminal endpoints included quantitative liver histology and transcriptome signatures as well as blood and liver biochemistry. PF-05231023 significantly reduced body weight, hepatomegaly, plasma transaminases, and plasma/liver lipids in GAN DIO-NASH mice. Notably, PF-05231023 reduced both NAS (≥2-point improvement) and fibrosis stage (1-point improvement). Improvements in NASH and fibrosis severity were supported by reduced quantitative histological markers of steatosis, inflammation, and fibrogenesis as well as improvements in disease-associated liver transcriptome signatures. In conclusion, PF-05231023 reduces NASH and fibrosis severity in a translational biopsy-confirmed mouse model of NASH, supporting development of FGF21 analogs for the treatment of NASH.NEW & NOTEWORTHY It is unclear if long-acting FGF21 analogs have antifibrotic efficacy in NASH. We therefore profiled the clinically relevant FGF21 analog PF-05231023 in a translational diet-induced

Published
2023

33. Hepatoprotective effects of semaglutide, lanifibranor and dietary intervention in the GAN diet‐induced obese and biopsy‐confirmed mouse model of NASH

Author

Møllerhøj, Mathias B., Veidal, Sanne S., Thrane, Kirstine Tølbøl, Oró, Denise, Overgaard, Agnete, Salinas, Casper Gravesen, Madsen, Martin Rønn, Pfisterer, Larissa, Vyberg, Mogens, Simon, Eric, Broermann, Andre, Vrang, Niels, Jelsing, Jacob, Feigh, Michael, and Hansen, Henrik H.

Subjects
Liver Cirrhosis, Male, Sulfonamides, Biopsy, General Neuroscience, Glucagon-Like Peptides, Mice, Obese, General Medicine, General Biochemistry, Genetics and Molecular Biology, Diet, Mice, Inbred C57BL, Disease Models, Animal, Mice, Liver, Non-alcoholic Fatty Liver Disease, Disease Progression, Animals, Humans, Benzothiazoles, Obesity, General Pharmacology, Toxicology and Pharmaceutics
Abstract

Non-alcoholic steatohepatitis (NASH) has emerged as a major challenge for public health because of high global prevalence and lack of evidence-based therapies. Most animal models of NASH lack sufficient validation regarding disease progression and pharmacological treatment. The Gubra-Amylin NASH (GAN) diet-induced obese (DIO) mouse demonstrate clinical translatability with respect to disease etiology and hallmarks of NASH. This study aimed to evaluate disease progression and responsiveness to clinically effective interventions in GAN DIO-NASH mice. Disease phenotyping was performed in male C57BL/6J mice fed the GAN diet high in fat, fructose, and cholesterol for 28-88 weeks. GAN DIO-NASH mice with biopsy-confirmed NASH and fibrosis received low-caloric dietary intervention, semaglutide (30 nmol/kg/day, s.c.) or lanifibranor (30 mg/kg/day, p.o.) for 8 and 12 weeks, respectively. Within-subject change in nonalcoholic fatty liver disease (NAFLD) Activity Score (NAS) and fibrosis stage was evaluated using automated deep learning-based image analysis. GAN DIO-NASH mice showed clear and reproducible progression in NASH, fibrosis stage, and tumor burden with high incidence of hepatocellular carcinoma. Consistent with clinical trial outcomes, semaglutide and lanifibranor improved NAS, whereas only lanifibranor induced regression in the fibrosis stage. Dietary intervention also demonstrated substantial benefits on metabolic outcomes and liver histology. Differential therapeutic efficacy of semaglutide, lanifibranor, and dietary intervention was supported by quantitative histology, RNA sequencing, and blood/liver biochemistry. In conclusion, the GAN DIO-NASH mouse model recapitulates various histological stages of NASH and faithfully reproduces histological efficacy profiles of compounds in advanced clinical development for NASH. Collectively, these features highlight the utility of GAN DIO-NASH mice in preclinical drug development.

Published
2022

36. Structurally‐engineered fatty acid 1024 (SEFA‐1024) improves diet‐induced obesity, insulin resistance, and fatty liver disease

Author

Secor, Jordon D., primary, Cho, Bennet S., additional, Yu, Lumeng J., additional, Pan, Amy, additional, Ko, Victoria H., additional, Dao, Duy T., additional, Feigh, Michael, additional, Anez‐Bustillos, Lorenzo, additional, Fell, Gillian L., additional, Fraser, David A., additional, Gura, Kathleen M., additional, and Puder, Mark, additional

Published
2022
Full Text
View/download PDF

39. Novel avenue towards liver regeneration and treatment of acute and chronic liver diseases: safety and PK profile from a first-in human (FIH) clinical trial for HRX-0215 as first in class MKK4 inhibitor

Author

Jung, Birgit, primary, Weissbach, Markus, additional, Lutz, Michael, additional, Selig, Roland, additional, Laufer, Stefan, additional, Zender, Lars, additional, Feigh, Michael, additional, Berse, Matthias, additional, Penski, Jette, additional, Kosmella, Esther, additional, and Albrecht, Wolfgang, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results